IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket Nos. 122, 290 & 339**

NOTICE OF FURTHER EXTENSION OF BID DEADLINE FOR (I) REMAINING ASSETS AND (II) PLAN SPONSOR ALTERNATIVE BIDS

PLEASE TAKE NOTICE that, on June 23, 2026, Sangamo Therapeutics, Inc., as debtor and debtor in possession (the "**Debtor**") in the above-captioned case (the "**Chapter 11 Case**"), filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code with the United States Bankruptcy Court for the District of Delaware (the "**Court**").

PLEASE TAKE FURTHER NOTICE that, on July 14, 2026, the Court entered the *Order (A) Approving Bidding Procedures for the Sale of the Debtor's Assets, (B) Approving the Debtor's Entry into the Stalking Horse APAs and Granting Bid Protections, (C) Authorizing the Debtor to Designate Additional Stalking Horse Bidders and Granting Bid Protections, (D) Approving Assumption and Rejection Procedures, (E) Scheduling an Auction and Sale Hearing and Approving Forms and Manner of Notice Thereof, and (F) Granting Related Relief* [Docket No. 122] (the "**Bidding Procedures Order**"), which, among other things: (i) approved procedures (the "**Bidding Procedures**")[2] to be used in connection with one or more Sales of substantially all of the Debtor's Assets, (ii) established a Bid Deadline for interested parties to submit Bids for the Assets, and (iii) scheduled an Auction for the Assets and a Sale Hearing to consider approval of the Sale(s).

PLEASE TAKE FURTHER NOTICE that on August 19, 2026, the Debtor filed the *Notice of Extended Bid Deadline for (I) Remaining Assets and (II) Plan Sponsor Alternative Bids* [Docket No. 339], extending the Bid Deadline with respect to any Bids for the Remaining Assets and Plan Sponsor Alternative Bids to August 31, 2026 at 5:00 p.m. (Eastern Time).

PLEASE TAKE FURTHER NOTICE that, in accordance with the Bidding Procedures, the Debtor has further extended the Bid Deadline with respect to any Bids for the Remaining Assets and Plan Sponsor Alternative Bids through and including the date upon which an order of the Court confirming a chapter 11 plan in the Chapter 11 Case (the "**Extended Bid Deadline**") becomes a final, non-appealable order. For the avoidance of any doubt, parties that submitted

[1] The debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The debtor's mailing address is 501 Canal Blvd., Ste A100, Richmond, CA 94804.

[2] Capitalized terms used but not defined herein have the meanings given to them in the Bidding Procedures or the Bidding Procedures Order, as applicable.

2610989260827000000000004

Qualified Bids for the Remaining Assets or for a Plan Sponsor Alternative prior to the previously established Bid Deadline **do not** need to submit revised bids prior to the Extended Bid Deadline unless they wish to improve the terms of their Bid. All previously submitted Qualified Bids for the Remaining Assets and Plan Sponsor Alternatives remain binding as set forth in the Bidding Procedures. **The Debtor reserves the right, pursuant to the Bidding Procedures, to further modify the Extended Bid Deadline in accordance with its business judgment and take any action that the Debtor determines in good faith is required in order for the Debtor or its Board of Directors to comply with their fiduciary duties under applicable law or the Bankruptcy Code.**

PLEASE TAKE FURTHER NOTICE that, pursuant to the Bidding Procedures, the Auction with respect to the Remaining Assets, if necessary, is adjourned to a date and time to be determined and such Auction, if any, shall be held at such time and place as shall be subsequently noticed.

PLEASE TAKE FURTHER NOTICE that the Debtor intends to file a chapter 11 plan on or before September 25, 2026.

PLEASE TAKE FURTHER NOTICE that, copies of the Bidding Procedures Motion, the Bidding Procedures Order, the Bidding Procedures, and the Notice of Successful Bidders may be obtained free of charge by visiting the Verita Website https://www.veritaglobal.net/sangamotherapeutics.

[*Remainder of page intentionally left blank*]

Dated: August 27, 2026
Wilmington, Delaware

/s/ Katherine R. Strauch

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
Katherine R. Strauch (No. 7667)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
strauch@rlf.com
and

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com
and

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession